Details for New Drug Application (NDA): 009102
✉ Email this page to a colleague
NDA 009102 describes ANTEPAR, which is a drug marketed by Glaxosmithkline and is included in one NDA. Additional details are available on the ANTEPAR profile page.
The generic ingredient in ANTEPAR is piperazine citrate. There are eighteen drug master file entries for this compound. Additional details are available on the piperazine citrate profile page.
The generic ingredient in ANTEPAR is piperazine citrate. There are eighteen drug master file entries for this compound. Additional details are available on the piperazine citrate profile page.
Summary for 009102
| Tradename: | ANTEPAR |
| Applicant: | Glaxosmithkline |
| Ingredient: | piperazine citrate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SYRUP;ORAL | Strength | EQ 500MG BASE/5ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 500MG BASE | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
